Cinpanemab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Cinpanemab (BIIB054) 是一种人源单克隆抗体，可与 α-突触核蛋白 1-10 位残基结合。Cinpanemab 可用于研究帕金森病。

Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease.

——

Animal Model:C57BL/6JRccHsd WT mice, transgenic M83 mice expressing human α-syn A53T, and transgenic bacterial artificial chromosome mice expressing human α-syn A53T were anesthetized and stereotaxically injected with α-syn preformed fibrils (PFFs) into the right forebrain Dosage:30 mg/kg Administration:Intraperitoneal (i.p.) injections 2-3 times prior to α-syn PFF injection and weekly post-injection until time of sacrifice Result:Attenuated the spreading of α-syn pathology, rescued motor impairments, and reduced the loss of dopamine transporter density in dopaminergic terminals in striatum.

——

Others

Other Targets

Others

——

——

2094516-02-4

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years